Forbion Raises €2.3B for European Biotech
Forbion raised €2.3B for life-sciences investing, strengthening European biotech capital formation.
European biotech companies need deep pools of specialist capital to move through long clinical and regulatory timelines.
What happened
Forbion raised €2.3B for life-sciences investing, increasing its assets under management to around €7.5B. The raise gives the firm more capital to back biotech companies across stages.
Why it matters
Large specialist funds matter in biotech because promising companies often require multiple rounds before clinical proof points or exits. More dedicated capital can help European science stay financed through development rather than selling too early.
The bigger picture
Biotech investing is capital intensive and cyclical. Forbion’s raise is a strong signal that European life sciences still has institutional support despite tougher funding markets.